CommercialCoverageMedium impact
Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
Blue Cross & Blue Shield of Mississippi·MS · Urology, OB-GYN, Family Medicine·Medical Policy
We identified it
Jun 20, 2026
Summary
BCBS MS has updated their medical policy for injectable bulking agents used to treat urinary and fecal incontinence. The policy clarifies that certain FDA-approved bulking agents (carbon-coated spheres, calcium hydroxylapatite, polyacrylamide hydrogel, or polydimethylsiloxane) are considered medically necessary for stress urinary incontinence after failed conservative therapy, while most other bulking agents and uses for fecal incontinence remain investigational.
Action Required
Immediately: Review current billing practices for injectable bulking agent procedures to ensure medical necessity documentation includes evidence of failed conservative therapy (minimum 3 months of pelvic floor exercises, behavioral changes, etc.). Update prior authorization requests to specify the exact bulking agent being used and confirm it's an FDA-approved product covered under the policy. Claims for investigational bulking agents or uses may be denied.